BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46:85-95. [PMID: 28464369 DOI: 10.1111/apt.14112] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 14.8] [Reference Citation Analysis]
Number Citing Articles
1 Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54:1013-25. [PMID: 34416040 DOI: 10.1111/apt.16575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Lonardo A. Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. Future Med Chem 2019;11:2171-92. [PMID: 31538528 DOI: 10.4155/fmc-2019-0003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
3 Tuong TTK, Tran DK, Phu PQT, Hong TND, Dinh TC, Chu DT. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan. Diagnostics (Basel). 2020;10. [PMID: 32183383 DOI: 10.3390/diagnostics10030159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
4 Losurdo G, Castellaneta A, Rendina M, Carparelli S, Leandro G, Di Leo A. Systematic review with meta-analysis: De novo non-alcoholic fatty liver disease in liver-transplanted patients. Aliment Pharmacol Ther. 2018;47:704-714. [PMID: 29359341 DOI: 10.1111/apt.14521] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
5 Oral A, Sahin T, Turker F, Kocak E. Relationship Between Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease in Non-Obese Patients. Medicina (Kaunas). 2019;55. [PMID: 31533345 DOI: 10.3390/medicina55090600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
6 Ampuero J, Aller R, Gallego-Durán R, Banales JM, Crespo J, García-Monzón C, Pareja MJ, Vilar-Gómez E, Caballería J, Escudero-García D, Gomez-Camarero J, Calleja JL, Latorre M, Albillos A, Salmeron J, Aspichueta P, Lo Iacono O, Francés R, Benlloch S, Fernández-Rodríguez C, García-Samaniego J, Estévez P, Andrade RJ, Turnes J, Romero-Gómez M; HEPAmet Registry. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther 2018;48:1260-70. [PMID: 30353552 DOI: 10.1111/apt.15015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
7 Mellor TE, Torres DM. Editorial: lean and obese NAFLD-similar siblings. Aliment Pharmacol Ther 2017;46:549-50. [DOI: 10.1111/apt.14196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Kountouras J, Polyzos SA, Katsinelos P, Doulberis M, Zavos C, Kazakos E, Boziki M, Tzivras D, Kotronis G. Letter : Helicobacter pylori in lean and obese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:637-8. [DOI: 10.1111/apt.14222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 Pirola CJ, Salatino A, Sookoian S. Pleiotropy within gene variants associated with nonalcoholic fatty liver disease and traits of the hematopoietic system. World J Gastroenterol 2021; 27(4): 305-320 [PMID: 33584064 DOI: 10.3748/wjg.v27.i4.305] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lu FB, Hu ED, Xu LM, Chen L, Wu JL, Li H, Chen DZ, Chen YP. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2018;12:491-502. [PMID: 29609501 DOI: 10.1080/17474124.2018.1460202] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
11 Shao C, Ye J, Li F, Feng S, Wang W, Zhong B. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. Digestive and Liver Disease 2019;51:1392-9. [DOI: 10.1016/j.dld.2019.02.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Wang P, Qiang H, Song Y, Dang Y, Luan H, Cao L, Cui Q, Tian G. Association between Nonalcoholic Fatty Liver and Gensini Score in Patients with Coronary Heart Disease: A Cross-Sectional Study. Cardiology 2019;144:90-6. [PMID: 31665722 DOI: 10.1159/000502111] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 VanWagner LB, Armstrong MJ. Lean NAFLD: A not so benign condition? Hepatol Commun 2018;2:5-8. [PMID: 29404505 DOI: 10.1002/hep4.1143] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
14 Kang SY, Kim YJ, Park HS. Trends in the Prevalence of Non-Alcoholic Fatty Liver Disease and Its Future Predictions in Korean Men, 1998-2035. J Clin Med 2020;9:E2626. [PMID: 32823604 DOI: 10.3390/jcm9082626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Patoulias DI. Non-alcoholic fatty liver disease in patients with inflammatory bowel disease might boost cardiovascular disease burden. Arch Med Sci Atheroscler Dis 2019;4:e250-1. [PMID: 32368680 DOI: 10.5114/amsad.2019.90147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun 2018;2:48-57. [PMID: 29404512 DOI: 10.1002/hep4.1124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 16.0] [Reference Citation Analysis]
17 Molina-Molina E, Krawczyk M, Stachowska E, Lammert F, Portincasa P. Non-Alcoholic Fatty Liver Disease in Non-Obese Individuals: Prevalence, Pathogenesis and Treatment. Clin Res Hepatol Gastroenterol. 2019;43:638-645. [PMID: 31196707 DOI: 10.1016/j.clinre.2019.04.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
18 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 165] [Cited by in F6Publishing: 164] [Article Influence: 55.0] [Reference Citation Analysis]
19 Aneni EC, Bittencourt MS, Teng C, Cainzos-Achirica M, Osondu CU, Soliman A, Al-Mallah M, Buddoff M, Parise ER, Santos RD, Nasir K. The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study. Am J Prev Cardiol 2020;4:100097. [PMID: 34327473 DOI: 10.1016/j.ajpc.2020.100097] [Reference Citation Analysis]
20 Liyanagedera S, Williams RP, Veraldi S, Nobili V, Mann JP. The pharmacological management of NAFLD in children and adolescents. Expert Rev Clin Pharmacol 2017;10:1225-37. [PMID: 28803504 DOI: 10.1080/17512433.2017.1365599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
21 Iritani S, Akuta N, Kawamura Y, Kajiwara A, Kasuya K, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saito S, Suzuki F, Arase Y, Ikeda K, Suzuki Y, Kumada H. Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. BMC Gastroenterol 2020;20:368. [PMID: 33148171 DOI: 10.1186/s12876-020-01509-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Wong RJ, Liu B, Bhuket T. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2017;46:974-980. [PMID: 28914448 DOI: 10.1111/apt.14327] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
23 Khayyat YM. Lean non-alcoholic fatty liver disease and associated metabolic disturbance: A Saudi Arabian cross-sectional study. Physiol Rep 2021;9:e14949. [PMID: 34278728 DOI: 10.14814/phy2.14949] [Reference Citation Analysis]
24 Chiu LS, Pedley A, Massaro JM, Benjamin EJ, Mitchell GF, McManus DD, Aragam J, Vasan RS, Cheng S, Long MT. The association of non-alcoholic fatty liver disease and cardiac structure and function-Framingham Heart Study. Liver Int 2020;40:2445-54. [PMID: 32654390 DOI: 10.1111/liv.14600] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Antonucci L, Porcu C, Iannucci G, Balsano C, Barbaro B. Non-Alcoholic Fatty Liver Disease and Nutritional Implications: Special Focus on Copper. Nutrients 2017;9:E1137. [PMID: 29057834 DOI: 10.3390/nu9101137] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
26 Golabi P, Paik JM, Arshad T, Younossi Y, Mishra A, Younossi ZM. Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. Hepatol Commun 2020;4:1136-48. [PMID: 32766474 DOI: 10.1002/hep4.1534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
27 Wong VW, Wong GL, Chan RS, Shu SS, Cheung BH, Li LS, Chim AM, Chan CK, Leung JK, Chu WC, Woo J, Chan HL. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69:1349-1356. [PMID: 30142427 DOI: 10.1016/j.jhep.2018.08.011] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
28 Rowe IA, Wong VW, Loomba R. Treatment Candidacy for Pharmacologic Therapies for NASH. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
29 Adinolfi LE, Marrone A, Rinaldi L. Non-alcoholic fatty liver disease: beyond the liver is an emerging multifaceted systemic disease. Hepatobiliary Surg Nutr 2018;7:143-6. [PMID: 29744347 DOI: 10.21037/hbsn.2018.02.01] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
30 Dietrich CG, Rau M, Geier A. Screening for nonalcoholic fatty liver disease-when, who and how? World J Gastroenterol 2021; 27(35): 5803-5821 [PMID: 34629804 DOI: 10.3748/wjg.v27.i35.5803] [Reference Citation Analysis]
31 Bernhardt P, Kratzer W, Schmidberger J, Graeter T, Gruener B; EMIL Study Group. Laboratory parameters in lean NAFLD: comparison of subjects with lean NAFLD with obese subjects without hepatic steatosis. BMC Res Notes 2018;11:101. [PMID: 29409538 DOI: 10.1186/s13104-018-3212-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
32 Argo CK, Stine JG, Henry ZH, Lackner C, Patrie JT, Weltman AL, Caldwell SH. Physical deconditioning is the common denominator in both obese and overweight subjects with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2018;48:290-9. [PMID: 29797529 DOI: 10.1111/apt.14803] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
33 Huanan C, Sangsang L, Amoah AN, Yacong B, Xuejiao C, Zhan S, Guodong W, Jian H, Songhe S, Quanjun L. Relationship between triglyceride glucose index and the incidence of non-alcoholic fatty liver disease in the elderly: a retrospective cohort study in China. BMJ Open 2020;10:e039804. [PMID: 33247011 DOI: 10.1136/bmjopen-2020-039804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Leung JC, Wong VW. Editorial: non-alcoholic fatty liver disease-it is better to be slender after all. Aliment Pharmacol Ther 2018;47:305-6. [PMID: 29265466 DOI: 10.1111/apt.14432] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
35 Shi Y, Wang Q, Sun Y, Zhao X, Kong Y, Ou X, Jia J, Wu S, You H. The Prevalence of Lean/Nonobese Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2020;54:378-387. [PMID: 31651571 DOI: 10.1097/mcg.0000000000001270] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 22.0] [Reference Citation Analysis]
36 Xiao HH, Lu L, Poon CC, Chan CO, Wang LJ, Zhu YX, Zhou LP, Cao S, Yu WX, Wong KY, Mok DK, Wong MS. The lignan-rich fraction from Sambucus Williamsii Hance ameliorates dyslipidemia and insulin resistance and modulates gut microbiota composition in ovariectomized rats. Biomed Pharmacother 2021;137:111372. [PMID: 33761598 DOI: 10.1016/j.biopha.2021.111372] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Cordeiro A, Costa R, Andrade N, Silva C, Canabrava N, Pena MJ, Rodrigues I, Andrade S, Ramalho A. Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity? Clin Res Hepatol Gastroenterol 2020;44:394-402. [PMID: 32044284 DOI: 10.1016/j.clinre.2019.10.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
38 Kuchay MS, Martínez-Montoro JI, Choudhary NS, Fernández-García JC, Ramos-Molina B. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines 2021;9:1346. [PMID: 34680463 DOI: 10.3390/biomedicines9101346] [Reference Citation Analysis]
39 Ahmed OT, Gidener T, Mara KC, Larson JJ, Therneau TM, Allen AM. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00747-3. [PMID: 34265444 DOI: 10.1016/j.cgh.2021.07.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
40 Sookoian S, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycoechea M, Pirola CJ. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 2020;69:1483-91. [DOI: 10.1136/gutjnl-2019-318811] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 17.5] [Reference Citation Analysis]
41 Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-pinto H, Targher G, Lonardo A. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology & Hepatology 2018;12:351-67. [DOI: 10.1080/17474124.2018.1415756] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
42 Aby E, Saab S. Nonobese nonalcoholic fatty liver disease. Clin Liver Dis (Hoboken). 2017;10:130-133. [PMID: 30992772 DOI: 10.1002/cld.674] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
43 Dhaliwal J, Chavhan GB, Lurz E, Shalabi A, Yuen N, Williams B, Martincevic I, Amirabadi A, Wales PW, Lee W, Ling SC, Mouzaki M. Hepatic steatosis is highly prevalent across the paediatric age spectrum, including in pre-school age children. Aliment Pharmacol Ther 2018;48:556-63. [PMID: 29998462 DOI: 10.1111/apt.14900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
44 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 30.0] [Reference Citation Analysis]
45 Chung S, Shin EJ, Choi HK, Park JH, Hwang JT. Anacardic acid mitigates liver fat accumulation and impaired glucose tolerance in mice fed a high-fat and high-sucrose diet. Food Sci Nutr 2020;8:796-804. [PMID: 32148789 DOI: 10.1002/fsn3.1322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
46 Yılmaz Y, Kanı HT, Demirtaş CÖ, Kaya E, Sapmaz AF, Qutranji L, Alkayyali T, Batun KD, Batman M, Toy B, Çiftaslan A. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. Turk J Gastroenterol 2019;30:892-8. [PMID: 31258138 DOI: 10.5152/tjg.2019.19072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
47 Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2018;47:16-25. [DOI: 10.1111/apt.14401] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
48 Amirkalali B, Khoonsari M, Sohrabi MR, Ajdarkosh H, Motamed N, Maadi M, Nobakht H, Gholizadeh E, Zamani F. Relationship between dietary macronutrient composition and non-alcoholic fatty liver disease in lean and non-lean populations: a cross-sectional study. Public Health Nutr 2021;:1-13. [PMID: 33896439 DOI: 10.1017/S1368980021001762] [Reference Citation Analysis]
49 Satapathy SK, Jiang Y, Agbim U, Wu C, Bernstein DE, Teperman LW, Kedia SK, Aithal GP, Bhamidimarri KR, Duseja A, Maiwall R, Maliakkal B, Jalal P, Patel K, Puri P, Ravinuthala R, Wong VW, Abdelmalek MF, Ahmed A, Thuluvath PJ, Singal AK; for the Global NAFLD Consortium. Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. Liver Transpl 2019;26:68-79. [DOI: 10.1002/lt.25672] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
50 Carotti S, Aquilano K, Zalfa F, Ruggiero S, Valentini F, Zingariello M, Francesconi M, Perrone G, Alletto F, Antonelli-Incalzi R, Picardi A, Morini S, Lettieri-Barbato D, Vespasiani-Gentilucci U. Lipophagy Impairment Is Associated With Disease Progression in NAFLD. Front Physiol 2020;11:850. [PMID: 32765301 DOI: 10.3389/fphys.2020.00850] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
51 Phipps M, Wattacheril J. Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals. Frontline Gastroenterol 2020;11:478-83. [PMID: 33101626 DOI: 10.1136/flgastro-2018-101119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Tsunoda K, Kitano N, Kai Y, Jindo T, Uchida K, Arao T. Dose-response relationships of accelerometer-measured sedentary behaviour and physical activity with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2021;54:1330-9. [PMID: 34633105 DOI: 10.1111/apt.16631] [Reference Citation Analysis]
53 Chan WK, Treeprasertsuk S, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Fan JG, Song MJ, Yoon SK, Dan YY, Lesmana L, Ho KY, Goh KL, Wong VW. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. Aliment Pharmacol Ther. 2018;47:816-825. [PMID: 29333610 DOI: 10.1111/apt.14506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
54 Tirosh O. Hypoxic Signaling and Cholesterol Lipotoxicity in Fatty Liver Disease Progression. Oxid Med Cell Longev 2018;2018:2548154. [PMID: 29955245 DOI: 10.1155/2018/2548154] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
55 Asadipooya K, Lankarani KB, Raj R, Kalantarhormozi M. RAGE is a Potential Cause of Onset and Progression of Nonalcoholic Fatty Liver Disease. Int J Endocrinol 2019;2019:2151302. [PMID: 31641351 DOI: 10.1155/2019/2151302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
56 Fridén M, Rosqvist F, Kullberg J, Ahlström H, Lind L, Risérus U. Associations between fatty acid composition in serum cholesteryl esters and liver fat, basal fat oxidation, and resting energy expenditure: a population-based study. Am J Clin Nutr 2021:nqab221. [PMID: 34225361 DOI: 10.1093/ajcn/nqab221] [Reference Citation Analysis]
57 Thompson DS, Tennant IA, Soares DP, Osmond C, Byrne CD, Forrester TE, Boyne MS. Nonalcoholic Fatty Liver Disease in Nonobese Subjects of African Origin Has Atypical Metabolic Characteristics. J Endocr Soc 2019;3:2051-63. [PMID: 31637346 DOI: 10.1210/js.2019-00138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Di Costanzo A, Belardinilli F, Bailetti D, Sponziello M, D'Erasmo L, Polimeni L, Baratta F, Pastori D, Ceci F, Montali A, Girelli G, De Masi B, Angeloni A, Giannini G, Del Ben M, Angelico F, Arca M. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Sci Rep 2018;8:3702. [PMID: 29487372 DOI: 10.1038/s41598-018-21939-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
59 Sung KC, Seo DC, Lee SJ, Lee MY, Wild SH, Byrne CD. Non alcoholic fatty liver disease and risk of incident diabetes in subjects who are not obese. Nutr Metab Cardiovasc Dis 2019;29:489-95. [PMID: 30940491 DOI: 10.1016/j.numecd.2019.01.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
60 Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021;36:1497-507. [PMID: 33217052 DOI: 10.1111/jgh.15353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
61 Hsu CL, Wu FZ, Lin KH, Chen YH, Wu PC, Chen YH, Chen CS, Wang WH, Mar GY, Yu HC. Role of Fatty Liver Index and Metabolic Factors in the Prediction of Nonalcoholic Fatty Liver Disease in a Lean Population Receiving Health Checkup. Clin Transl Gastroenterol. 2019;10:1-8. [PMID: 31082856 DOI: 10.14309/ctg.0000000000000042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
62 Shao C, Ye J, Li F, Lin Y, Wu T, Wang W, Feng S, Zhong B. Early Predictors of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease: Non-obese Versus Obese Patients. Dig Dis Sci. 2020;65:1850-1860. [PMID: 31724099 DOI: 10.1007/s10620-019-05926-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
63 Pirola CJ, Sookoian S. The lipidome in nonalcoholic fatty liver disease: actionable targets. J Lipid Res 2021;62:100073. [PMID: 33845089 DOI: 10.1016/j.jlr.2021.100073] [Reference Citation Analysis]
64 Maier S, Wieland A, Cree-Green M, Nadeau K, Sullivan S, Lanaspa MA, Johnson RJ, Jensen T. Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord 2021;22:351-66. [PMID: 33389543 DOI: 10.1007/s11154-020-09621-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Arvind A, Henson JB, Osganian SA, Nath C, Steinhagen LM, Memel ZN, Donovan A, Balogun O, Chung RT, Simon TG, Corey KE. Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021. [PMID: 34558862 DOI: 10.1002/hep4.1818] [Reference Citation Analysis]
66 Navarroza AMC, Wong SN. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease. Indian J Gastroenterol 2021. [PMID: 34213749 DOI: 10.1007/s12664-021-01184-6] [Reference Citation Analysis]
67 Ariya M, Koohpayeh F, Ghaemi A, Osati S, Davoodi SH, Razzaz JM, Javedan G, Ehrampoush E, Homayounfar R. Assessment of the association between body composition and risk of non-alcoholic fatty liver. PLoS One 2021;16:e0249223. [PMID: 33793621 DOI: 10.1371/journal.pone.0249223] [Reference Citation Analysis]
68 Mao L, Lei J, Schoemaker MH, Ma B, Zhong Y, Lambers TT, Van Tol EAF, Zhou Y, Nie T, Wu D. Long-chain polyunsaturated fatty acids and extensively hydrolyzed casein-induced browning in a Ucp-1 reporter mouse model of obesity. Food Funct 2018;9:2362-73. [DOI: 10.1039/c7fo01835e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
69 Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol 2017; 23(36): 6571-6592 [PMID: 29085206 DOI: 10.3748/wjg.v23.i36.6571] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 71] [Article Influence: 16.0] [Reference Citation Analysis]
70 Umehara T. Nonalcoholic fatty liver disease with elevated alanine aminotransferase levels is negatively associated with bone mineral density: Cross-sectional study in U.S. adults. PLoS One 2018;13:e0197900. [PMID: 29897928 DOI: 10.1371/journal.pone.0197900] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
71 Zou ZY, Wong VW, Fan JG. Epidemiology of nonalcoholic fatty liver disease in non‐obese populations: Meta‐analytic assessment of its prevalence, genetic, metabolic, and histological profiles. J Dig Dis 2020;21:372-84. [DOI: 10.1111/1751-2980.12871] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
72 Kuo Y, Kee K, Wang J, Hsu N, Hsiao C, Chen Y, Lu S. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. Aliment Pharmacol Ther 2018;48:993-1002. [DOI: 10.1111/apt.14960] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
73 Wang H, Gao Q, He S, Bao Y, Sun H, Meng L, Liang J, Sun C, Chen S, Cao L, Huang W, Zhang Y, Huang J, Wu S, Wang T. Self-reported snoring is associated with nonalcoholic fatty liver disease. Sci Rep 2020;10:9267. [PMID: 32518245 DOI: 10.1038/s41598-020-66208-1] [Reference Citation Analysis]
74 Zelber-Sagi S. Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations. Semin Liver Dis 2021;41:248-62. [PMID: 34139786 DOI: 10.1055/s-0041-1729971] [Reference Citation Analysis]
75 Masroor M, Haque Z. HbA1C as a Biomarker of Non-alcoholic Fatty Liver Disease: Comparison with Anthropometric Parameters. J Clin Transl Hepatol 2021;9:15-21. [PMID: 33604251 DOI: 10.14218/JCTH.2019.00046] [Reference Citation Analysis]
76 Cherubini A, Casirati E, Tomasi M, Valenti L. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets 2021;:1-11. [PMID: 34904923 DOI: 10.1080/14728222.2021.2018418] [Reference Citation Analysis]